Publications by authors named "K Benkali"
Aims: Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab or ravulizumab. Crovalimab showed efficacy and safety comparable to eculizumab in the pivotal COMMODORE 2 and supporting studies.
Methods: We characterized crovalimab pharmacokinetics and the relationship between exposure pharmacokinetic parameters and pharmacodynamic biomarkers, efficacy and safety endpoints using pooled data (healthy volunteers [n = 9], naive [n = 210] and switched [n = 211] patients).
Article Synopsis
- Nemolizumab is a monoclonal antibody that targets the interleukin-31 receptor, helping to reduce itching and inflammation in patients with moderate-to-severe atopic dermatitis (AD).
- Clinical trials demonstrated that weight-based dosing effectively lessened pruritus with a good safety profile, leading to the development of a flat dosing regimen for easier administration.
- The selected flat dose of 30 mg, with a 60 mg loading dose every 4 weeks, was supported by pharmacokinetic studies and proved effective in improving symptoms of AD in ongoing phase 3 studies.
Trifarotene is a new drug with retinoic acid receptor activity and selectivity for retinoic acid receptor-γ. The reported studies aimed at assessing the clinical pharmacology and safety of trifarotene. The clinical pharmacology of topical trifarotene up to 100 µg/g was extensively investigated through 2 maximal usage pharmacokinetic trials (MUsT) conducted in adult (≥18 years) and pediatric patients (9-17 years) with moderate to severe acne and two studies conducted in healthy volunteers: 1 thorough QT study and 1 drug-drug interaction study with concomitantly administered oral levonorgestrel (0.
View Article and Find Full Text PDFPurpose: To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and non-lesional psoriatic skin when released from a commercially available low-strength cream using in vivo dermal open-flow microperfusion (dOFM).
Methods: Twelve patients received Dermovate® cream (CP-17, 0.05%) on small lesional and non-lesional skin test sites for 14 days, once daily.
Background: Persistent facial erythema is the most common primary pathological feature of rosacea, the only treatment for which is brimonidine tartrate (BT) gel.
Objectives: To assess the relative bioavailability of topical BT gel in comparison with the ophthalmic BT solution.
Methods: A pharmacokinetic study was conducted to compare intraindividual systemic exposures after dermal application of BT gel (0·07%, 0·18% and 0·5%) under maximal use conditions in patients with moderate-to-severe facial erythema associated with rosacea, and administration of BT ophthalmic solution 0·2%.